Literature DB >> 466646

Tumor therapy by deprivation of L-methionine: rationale and results.

W Kreis.   

Abstract

Published reports indicate that normal rodent cells can grow in medium containing either L-methionine or L-homocysteine, whereas malignant rodent cells have an absolute requirement for L-methionine. Our studies with two normal human cell lines (fetal lung fibroblasts and bladder epithelial cells) exhibit equal growth in media containing either L-methionine or L-homocysteine. The same is true for five malignant human cell lines (carcinoma of the cervix [HeLa], adenocarcinoma of the breast [AlAb], acute lymphoblastic leukemia [MOLT-3], Wilms' tumor [SK-NEP-1], and reticulum cell sarcoma [T-77], whereas four other malignant cell lines (adenocarcinoma of the breast [SK-BR-2-III], the two lymphoblastic leukemias [CCRF-HSB-2 and CCRF-SB], and a neuroblastoma [SK-N-MC]) have absolute requirements for L-methionine. Two malignant cell lines, an adenocarcinoma of the lung (A549) and an adenocarcinoma of the pancreas (Capan-1), showed restricted growth under the experimental conditions used. L-Methionlinase (L-methionine-alpha-deamino-gamma-mercaptomethane-lyase, EC 4.4.1.11) at a concentration of 0.1 unit/ml leads to complete growth inhibition of cell cultures of both the normal human fetal lung fibroblasts (F-136-35-56) and the acute lymphoblastic leukemia (CCRF-HSB-2). L-Homocysteine-thiolactone in medium containing L-methioninase could partly "rescue" the normal but not the malignant cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466646

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  13 in total

1.  Structural Snapshots of an Engineered Cystathionine-γ-lyase Reveal the Critical Role of Electrostatic Interactions in the Active Site.

Authors:  Wupeng Yan; Everett Stone; Yan Jessie Zhang
Journal:  Biochemistry       Date:  2017-02-03       Impact factor: 3.162

2.  Catalytic Roles of Coenzyme Pyridoxal-5'-phosphate (PLP) in PLP-dependent Enzymes: Reaction Pathway for Methionine-γ-lyase-catalyzed L-methionine Depletion.

Authors:  Zhe Li; Yunsong Zhao; Huifang Zhou; Hai-Bin Luo; Chang-Guo Zhan
Journal:  ACS Catal       Date:  2020-01-13       Impact factor: 13.084

Review 3.  Methionine dependence in cancer cells - a review.

Authors:  R M Hoffman
Journal:  In Vitro       Date:  1982-05

4.  S-adenosylmethionine limitation induces p38 mitogen-activated protein kinase and triggers cell cycle arrest in G1.

Authors:  Da-Wei Lin; Benjamin P Chung; Peter Kaiser
Journal:  J Cell Sci       Date:  2013-10-23       Impact factor: 5.285

5.  De novo engineering of a human cystathionine-γ-lyase for systemic (L)-Methionine depletion cancer therapy.

Authors:  Everett Stone; Olga Paley; Jian Hu; Barbara Ekerdt; Nai-Kong Cheung; George Georgiou
Journal:  ACS Chem Biol       Date:  2012-09-21       Impact factor: 5.100

6.  Methionine cytotoxicity in the human breast cancer cell line MCF-7.

Authors:  Hyung H Kim; Chung S Park
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Mar-Apr       Impact factor: 2.416

7.  Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells.

Authors:  D W Coalson; J O Mecham; P H Stern; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

8.  Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats.

Authors:  N Goseki; M Endo; T Onodera; G Kosaki
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

Review 9.  L-methionase: a therapeutic enzyme to treat malignancies.

Authors:  Bhupender Sharma; Sukhdev Singh; Shamsher S Kanwar
Journal:  Biomed Res Int       Date:  2014-08-31       Impact factor: 3.411

10.  Enhanced anticancer effect of vincristine with methionine infusion after methionine-depleting total parenteral nutrition in tumor-bearing rats.

Authors:  N Goseki; T Nagahama; M Maruyama; M Endo
Journal:  Jpn J Cancer Res       Date:  1996-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.